In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction

Transplant Immunology

Volumn 23, Issue 4, 2010, Pages 170-173

  Amet, Nurmamet ^a   Gacad, Mercedes ^a   Petrosyan, Anna ^a   Pao, Andy ^a   Jordan, Stanley C ^a   Toyoda, Mieko ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Apoptosis induction; Cell proliferation; Everolimus; Intravenous immunoglobulin; Mixed lymphocyte reaction; Synergistic effect

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; EVEROLIMUS; IMMUNOGLOBULIN; UNCLASSIFIED DRUG; ZORTRESS;

APOPTOSIS; ARTICLE; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL;

ANTIGENS, CD19; ANTIGENS, CD3; APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; LYMPHOCYTE CULTURE TEST, MIXED; SIROLIMUS; T-LYMPHOCYTES;

EID: 77956064602     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.06.012     Document Type: Article

References (24)

1. Nashan B., Curtis J., Ponticelli C., Mourad G., Jaffe J., Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004, 78:1332.
2. Eisen H.J., Tuzcu E.M., Dorent R., Kobashigawa J., Mancini D., Valantine-von Kaeppler H.A. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients 2003, 847-858.
3. Marti H.P., Frey F.J. Nephrotoxicity of rapamycin: an emerging problem in clinical medicine 2005, 13-15. ERA-EDTA.
4. Lehmkuhl H.B., Mai D., Dandel M., Knosalla C., Hiemann N.E., Grauhan O., et al. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 2007, 26:700-704.
5. Lorber M.I., Ponticelli C., Whelchel J., Mayer H.W., Kovarik J., Li Y., et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005, 19:145-152.
6. Schuler W., Sedrani R., Cottens S. H‰berlin B, Schulz M, Schuurman HJ, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997, 64:36.
7. Augustine J.J., Hricik D.E. Experience with everolimus 2004, 500-503. Elsevier.
8. Vignot S., Faivre S., Aguirre D., Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005, 16:525-537.
9. Boulay A., Zumstein-Mecker S., Stephan C., Beuvink I., Zilbermann F., Haller R. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells 2004, 252-261. AACR.
10. Vitko S., Tedesco H., Eris J., Pascual J., Whelchel J., Magee J.C., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004, 4:626.
11. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001, 345:747-755.
12. Jordan S.C., Tyan D., Stablein D., McIntosh M., Rose S., Vo A. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. Am Soc Nephrol 2004, 3256-3262.
13. Vo A.A., Lukovsky M., Toyoda M., Wang J., Reinsmoen N.L., Lai C.H., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008, 359:242.
14. Stanley C.J., Ashley A.V., Mieko T., Dolly T., Cynthia C.N. Post-transplant therapy with high-dose intravenous gammaglobulin: applications to treatment of antibody-mediated rejection. Pediatr Transplant 2005, 9:155-161.
15. Jordan S.C., Toyoda M., Vo A.A. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009, 88:1.
16. Toyoda M., Zhang X.M., Petrosian A., Wachs K., Moudgil A., Jordan S.C. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. Transpl Immunol 1994, 2:337.
17. Jordan S.C., Vo A., Bunnapradist S., Toyoda M., Peng A., Puliyanda D., et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003, 76:631-636.
18. Bayry J., Bansal K., Kazatchkine M.D., Kaveri S.V. DC-SIGN and 2, 6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Nat Acad Sci 2009, 106:E24.
19. Toyoda M., Petrosyan A., Pao A., Jordan S.C. Immunomodulatory effects of combination of pooled human gammaglobulin and rapamycin on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transplantation 2004, 78:1134.
20. Mahalati K., Kahan B.D. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001, 40:573.
21. Lutz J., Zou H., Liu S., Antus B., Heemann U. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 2003, 76:508.
22. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., OíReilly T., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759.
23. Mabuchi S., Altomare D.A., Cheung M., Zhang L., Poulikakos P.I., Hensley H.H., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007, 13:4261.
24. Strauss WOaK-MD G. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002, 128:255-266.